In a different trial (NCT06518837), tirzepatide will be evaluated in patients during adjuvant treatment for breast cancers that are hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative, the most prevalent breast cancer subtype. Here, HR is linked to breast carcinoma.